Jazz Pharmaceuticals

VYXEOS

Manufacturer:

Jazz Pharmaceuticals

Vyxeos HCPCS:

J9153

HCPCS Code Descriptor:

Injection, liposomal, 1 mg daunorubicin and 2.27 mg cytarabine

Category:

J Code

Vyxeos NDCs:

68727-0745-05, 68727-0745-01, 68727-0745-02

Primary Type:

Oncology

Generic/Specialty Status:

Single-Source

Package Type:

Vial

Route of Administration:

Intravenous

Potential NDC Listing Errors:

Our team has identified potential listing errors/discrepancies with the following NDCs:

68727-0745-05, 68727-0745-02

About Vyxeos:

VYXEOS is an Oncology drug manufactured by Jazz Pharmaceuticals and administered via the Intravenous route of administration. The J Code: J9153 is aligned to the drug VYXEOS.

ACCESS PRICING AND MORE BY REGISTERING

J9153 Added Date:

January 1, 2019

J9153 Effective Date:

January 1, 2019

J9153 Termination Date:

HCPCS Active

We have not yet identified a manufacturer source of Vyxeos billing and coding information.
Vyxeos patient assistance information can be found through JazzCares at the URL: https://www.jazzcares.com/
VYXEOS prescribing information can be found at the link below:
Information regarding VYXEOS’s side effects can be found at MedlinePlus